<DOC>
	<DOCNO>NCT01705873</DOCNO>
	<brief_summary>The objective study evaluate change Framingham score ( low moderate , moderate high ) base change lipid profile parameter baseline 48 week HAART naïve patient patient second line treatment , consider LPV/r v EFV base HAART . The null hyphotesis increase Framingham score patient treat LPV/r second line treatment patient treat LPV/r EFV regimen first line treatment .</brief_summary>
	<brief_title>Analysis Risk Cardiovascular Events HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. EFV Based Regimen</brief_title>
	<detailed_description>Study design duration : Retrospective comparative study . Estimated time enrollment : 12 month . Procedure : Retrospective review clinical chart : LPV/r ( n = 100 ) EFV ( randomly select representative sample patient EFV treatment : 200 patient approximately. ) . Each patient include one arm study ( switch EFV LPV/r LPV/r EFV ) Subject population LPV/r ( n = 100 ) EFV ( randomly select representative sample patient EFV treatment : 200 patient approximately. ) . Each patient include one arm study ( switch EFV LPV/r LPV/r EFV ) Study Objectives : Primary Objectives 1 ) Changes Framingham score ( low moderate , moderate high ) base change lipid profile parameter baseline 48 week HAART naïve patient patient second line treatment Secondary Objectives 1 . Risk assessment hazard CV event HIV- infected subject treat LPV/r second line EFV LPV/r first line base HAART regimen whole population study female male subpopulation . 2 . Assessment 10- year risk develop hard cardiovascular event ( myocardial infarction coronary death ) HIV- infected subject treat LPV/r ( 1° 2° line ) EFV first line base HAART regimen 3 . Overall mortality ( include CV event ) HIV- infected subject treat LPV/r second line EFV LPV/r first line base HAART regimen 4 . Evolution lipid profile ( total cholesterol , HDL , LDL triglicerides ) lipid lower agent requirement : baseline vs. 48 week initiation LPV/r second line base HAART regimen LPV/r EFV first line base HAART regimen 5 . Assesment CD4 T-cell count viral load baseline 48 week regimen .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion criterion 1 . HIV positive patient ( confirmation ELISA + W. blot require ) . 2 . Age ≥ 18 year . 3 . Naïve experience antiretroviral drug . 4 . LPV/r EFV first line regimen . 5 . In patient LPV/r second line HAART regimen , prior exposure NNRTI regimen acceptable . 6 . Time exposure LPV/r EFV least 48 week . Exclusion criterion : 1 . Age &lt; 18 yr . 2 . Already LPV/r treatment admission institution ( prevents assessment baseline lipid profile CV risk patient receive `` first dose '' either LPV/r ) 3 . Patients receive LPV/r pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>risk</keyword>
	<keyword>mortality</keyword>
</DOC>